1. Scrip
  2. >>Business
  3. >>Deals

Tough Going Forces Chinese Biotechs To Form Domestic Alliances

 
• By Brian Yang

Deals among domestic Chinese biotechs are growing fast, reflecting a need to huddle up amid tightening scrutiny over biotech deal-making and an unusually competitive immuno-oncology market.

Hands
Chinese biotechs bundle up to compete in a toughening environment • Source: Shutterstock

Just several months ago, cross-border deals between Chinese biotechs and overseas firms had been sizzling hot. But now the activity has notably declined and instead, Chinese bioventures are increasingly looking among themselves for collaboration.

Examples abound. Days after a week-long Lunar New Year celebration in February, several Chinese startups signed multiple agreements, ranging from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Shigella Vaccine Pipeline And Why It Matters

 
• By Vibha Ravi

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.

More from Business

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.